title: Involvement of NMDA receptor complex in the anxiolytic-like effects of chlordiazepoxide in mice.
abstract: In the present study, we demonstrated that low, ineffective doses of N-methyl-D-aspartic acid (NMDA) receptor antagonists [competitive NMDA antagonist, CGP 37849, at 0.312 mg/kg intraperitoneally (i.p.), antagonist of the glycine(B) sites, L-701,324, at 2 mg/kg i.p., partial agonist of glycine(B) sites, D-cycloserine, at 2.5 mg/kg i.p.] administered jointly with an ineffective dose of the benzodiazepine, chlordiazepoxide (CDP, 2.5 mg/kg i.p.), significantly increased the percentage of time spent in the open arms of the elevated plus-maze (index of anxiolytic effect). Furthermore, CDP-induced anxiolytic-like activity (5 mg/kg i.p.) was antagonized by NMDA (75 mg/kg i.p.) and by an agonist of glycine(B) sites of the NMDA receptor complex, D-serine [100 nmol/mouse intracerebroventricularly (i.c.v.)]. The present study showed a positive interaction between γ-aminobutyric acid (GABA) and glutamate neurotransmission in the anxiolytic-like activity in the elevated plus-maze test in mice and this activity seems to particularly involve the NMDA receptors.
authors.affiliation: Department of Applied Pharmacy, Medical University of Lublin, Chodźki 1, 20-093 Lublin, Poland. ewa.poleszak@umlub.pl
authors.forename: Ewa
authors.initials: E
authors.lastname: Poleszak
authors.forename: Katarzyna
authors.initials: K
authors.lastname: Socała
authors.forename: Aleksandra
authors.initials: A
authors.lastname: Szopa
authors.forename: Andrzej
authors.initials: A
authors.lastname: Wróbel
authors.forename: Bernadeta
authors.initials: B
authors.lastname: Szewczyk
authors.forename: Regina
authors.initials: R
authors.lastname: Kasperek
authors.forename: Eliza
authors.initials: E
authors.lastname: Blicharska
authors.forename: Gabriel
authors.initials: G
authors.lastname: Nowak
authors.forename: Piotr
authors.initials: P
authors.lastname: Wlaź
mesh_terms: D000818:Animals; D014151:Anti-Anxiety Agents / Q000494:pharmacology*; D001008:Anxiety Disorders / Q000188:drug therapy / Q000378:metabolism* / Q000503:physiopathology; D002707:Chlordiazepoxide / Q000494:pharmacology*; D018757:GABA Modulators / Q000494:pharmacology*; D018698:Glutamic Acid / Q000502:physiology; D008297:Male; D051379:Mice; D016194:Receptors, N-Methyl-D-Aspartate / Q000819:agonists / Q000037:antagonists & inhibitors / Q000502:physiology*; D005680:gamma-Aminobutyric Acid / Q000502:physiology
chemical_list: D014151:Anti-Anxiety Agents; D018757:GABA Modulators; D016194:Receptors, N-Methyl-D-Aspartate; D018698:Glutamic Acid; D005680:gamma-Aminobutyric Acid; D002707:Chlordiazepoxide